Insmed, Inc. (NASDAQ:INSM) Receives $203.45 Average Target Price from Brokerages

Shares of Insmed, Inc. (NASDAQ:INSM) have received a consensus recommendation of “Buy” from the twenty-four ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nineteen have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $204.2381.

A number of equities analysts have recently weighed in on INSM shares. UBS Group cut their price target on Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a report on Tuesday, January 6th. Guggenheim dropped their price objective on Insmed from $230.00 to $221.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Mizuho set a $212.00 target price on shares of Insmed in a research note on Thursday, December 18th. Roth Mkm upgraded shares of Insmed to a “strong-buy” rating in a report on Friday, January 23rd. Finally, Royal Bank Of Canada lifted their price target on shares of Insmed from $197.00 to $200.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st.

Insider Activity

In other news, CFO Sara Bonstein sold 748 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total transaction of $116,942.32. Following the sale, the chief financial officer owned 79,758 shares in the company, valued at $12,469,365.72. This trade represents a 0.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO William Lewis sold 13,396 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $147.79, for a total value of $1,979,794.84. Following the completion of the transaction, the chief executive officer owned 301,185 shares of the company’s stock, valued at $44,512,131.15. The trade was a 4.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 173,253 shares of company stock worth $29,629,842 in the last three months. 3.00% of the stock is owned by insiders.

Institutional Trading of Insmed

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Insmed by 5.7% during the 4th quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after acquiring an additional 1,140,524 shares during the period. Darwin Global Management Ltd. grew its holdings in Insmed by 2.3% in the fourth quarter. Darwin Global Management Ltd. now owns 20,933,277 shares of the biopharmaceutical company’s stock valued at $3,644,274,000 after purchasing an additional 475,832 shares during the period. Capital International Investors increased its position in Insmed by 1.0% during the third quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock worth $1,087,830,000 after purchasing an additional 74,994 shares during the last quarter. State Street Corp raised its stake in Insmed by 30.6% during the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock worth $905,312,000 after purchasing an additional 1,217,390 shares during the period. Finally, Artisan Partners Limited Partnership raised its stake in Insmed by 49.0% during the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock worth $711,076,000 after purchasing an additional 1,623,342 shares during the period.

Insmed Trading Up 1.2%

Shares of INSM opened at $150.52 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. The firm has a 50 day simple moving average of $167.22 and a 200-day simple moving average of $162.88. Insmed has a 1-year low of $60.40 and a 1-year high of $212.75. The stock has a market cap of $32.10 billion, a price-to-earnings ratio of -24.32 and a beta of 1.11.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.